Phase 2 study of ANB019 in the patient with generalized pustular psoriasis

Trial Profile

Phase 2 study of ANB019 in the patient with generalized pustular psoriasis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 May 2018

At a glance

  • Drugs ANB 019 (Primary)
  • Indications Generalised pustular psoriasis
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 May 2018 Status changed from planning to recruiting, according to an AnaptysBio media release
    • 05 Mar 2018 According to an AnaptysBio media release, Company submitted a Clinical Trial Authorization, or CTA, filing with the U.K. Medicines and Healthcare Products Regulatory Agency, or MHRA
    • 19 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top